OAM
CADL icon

Oxford Asset Management’s Candel Therapeutics CADL Stock Holding History

Oxford Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,003
Closed -$104K – 506
2024
Q4 		$104K Buy
+12,003
New +$70.9K 0.05% 390

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Oxford Asset Management's CADL Position: Q1 2025 in Review

Oxford Asset Management sold out of Candel Therapeutics (CADL) in Q1 2025, closing a stake of 12,003 shares — an estimated $104K sold.

Oxford Asset Management first reported a position in CADL in Q4 2024 and held it in 1 quarter. The position peaked at $104K in Q4 2024. 82 funds tracked by Wall St. Rank hold CADL as of Q1 2025.

  • Oxford Asset Management reported no remaining Candel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Oxford Asset Management sold 12,003 Candel Therapeutics shares in Q1 2025, an estimated $104K.
  • Oxford Asset Management first reported a position in Candel Therapeutics in Q4 2024 and held it in 1 quarter.
  • Oxford Asset Management's Candel Therapeutics position peaked at $104K in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2025.

Based on Oxford Asset Management's 13F filing for Q1 2025, filed 15 May 2025.